At parenteral dose concentrations of 10–20 mg total extract solids per millilitre, the baicalin fraction (baicalein-7-O-glucuronide) in the veterinary-grade powder exhibits pH-dependent aqueous solubility that does not exceed 1 mg/mL at 25°C below pH 6.5. Solution preparation for injectable presentation therefore requires alkalisation to pH 7.5–8.0 using 0.1 mol/L sodium hydroxide, added over 15–20 minutes under continuous agitation at 300–500 rpm in a jacketed stainless steel vessel maintained at 25°C ± 2°C. The pH adjustment window is constrained by two competing degradation mechanisms: chlorogenic acid undergoes oxidative ring-opening to quinoid derivatives at pH above 8.5 and at solution temperatures above 60°C, while baicalin glucuronide hydrolyses measurably in alkaline media. Terminal sterilisation follows the Chinese Veterinary Pharmacopoeia injection monograph, which permits moist-heat cycles of 100°C for 30 minutes for containers of 50 mL or less when product thermolability is documented; larger container volumes require 115°C for 30 minutes. In practice, F0 accumulation at these cycles remains below 8 minutes, and the CVP therefore instructs that aseptic filling under Grade A laminar airflow with Grade B background is mandatory when the sterility assurance level is not fully delivered by the terminal cycle alone. Depyrogenation of the bulk solution uses activated carbon at 0.05–0.1% w/v, incubated at 60°C for 20 minutes, followed by clarification through a 0.45 µm PVDF cartridge and sterilising-grade filtration through a 0.22 µm PVDF cartridge. Endotoxin limits are established per USP <85> methodology, with the numerical threshold assigned by route of administration in the individual veterinary marketing authorisation; intravenous presentations commonly require not more than 0.5 EU/mg of administered dose, while intramuscular and subcutaneous products may be justified at higher thresholds. Particulate matter control follows USP <788>: containers of 100 mL or less must contain not more than 6,000 particles ≥ 10 µm per container and not more than 600 particles ≥ 25 µm per container; larger-volume presentations shift to 25 particles/mL ≥ 10 µm and 3 particles/mL ≥ 25 µm. Batch-to-batch variance in the extract powder total flavonoid content is typically ±10% relative standard deviation; pre-formulation assay normalisation by HPLC with UV detection at 280 nm for baicalin is therefore executed on every incoming lot, and fill volume is adjusted accordingly. The finished injectable is filled into Type I borosilicate glass ampoules or Type II glass vials with bromobutyl rubber closures, headspace nitrogen sparging at 0.2 L/min during filling reduces oxidative degradation of chlorogenic acid, and storage below 25°C in the absence of light is specified.

HPLC analysis of the injectable solution employs a C18 stationary phase (250 mm × 4.6 mm, 5 µm) with a mobile phase gradient of methanol and 0.2% v/v phosphoric acid; baicalin is detected at 280 nm, chlorogenic acid at 327 nm, and matrine and oxymatrine, contributed by the Sophora flavescens fraction of the powder, are quantified separately at 220 nm following alkaline buffer extraction. Related-substance limits for botanical injectables are typically set at not more than 2.0% for any single impurity and not more than 5.0% total impurities expressed as percentage of total peak area, under the Chinese Veterinary Pharmacopoeia HPLC general chapter. Sterility testing follows USP <71> with membrane filtration of the entire container contents; incubation at 30–35°C for aerobic bacteria and 20–25°C for fungi is extended through 14 days. Published data specific to this exact Shuanghuang Kuxian injectable configuration is limited; the physicochemical stability behaviour of baicalin and chlorogenic acid in aqueous parenteral solutions has, however, been characterised in compendial monographs for analogous botanical injectables.

Production-scale observations reported for analogous spray-dried botanical extracts indicate that the activated carbon depyrogenation step removes not only pyrogens but also a measurable fraction of the polyphenolic markers; the carbon dose and contact time must therefore be optimised at pilot scale to balance endotoxin reduction against active marker recovery. Ultrafiltration using polyethersulfone cassettes with 10,000 Da molecular weight cut-off provides equivalent pyrogen removal without the adsorptive losses associated with carbon, but the transmembrane pressure should be maintained below 1.0 bar to limit shear-induced aggregation of high-molecular-weight polysaccharides present in the extract. Filtration flux rates are typically 30–50 L/m²/h at 25°C on a 0.5 m² cassette, and the retentate fraction is discarded after a single pass. Full-scale injection batches of 500 L typically require pre-filtration through a 1.0 µm polypropylene depth filter to protect the sterilising-grade membrane; without this pre-filtration, the 0.22 µm filter can reach terminal pressure differential after 20–30 minutes of processing because of colloidal load from the extract.

Compression Dynamics of a Spray-Dried Botanical Extract Powder

Characterised by bulk density 0.45–0.60 g/cm³ and tapped density 0.65–0.85 g/cm³, the spray-dried extract powder entering the tablet route exhibits a Carr index of 28–35 and a Hausner ratio of 1.35–1.50. These powder flow indices preclude direct compression at tablet target weights of 500–800 mg with 200–400 mg extract per tablet because die-fill weight variability exceeds ±5% relative standard deviation on a 20-station rotary press. The manufacturing route is therefore shifted to wet granulation in a high-shear mixer — typically a 250 L horizontal ploughshare mixer with impeller speed 100–200 rpm and chopper speed 1,500–3,000 rpm — using a binder solution of povidone K30 at 2.5–5.0% w/w of the dry granulate mass or pregelatinised starch paste at 5–10% w/w. Wet massing time is limited to 3–5 minutes after binder addition because overgranulation shifts the granule size distribution toward coarse agglomerates that cause edge capping on subsequent compression. The wet granulate is transferred to a fluid bed dryer with inlet air temperature maintained at 50–60°C and product temperature held at 40–45°C; this thermal ceiling protects the chlorogenic acid fraction from oxidative degradation while still achieving the target loss on drying of 3.0–5.0% as determined by moisture balance at 105°C per USP <731>.

The dried granulate is milled through an oscillating granulator fitted with a 0.8–1.2 mm stainless steel screen and blended with microcrystalline cellulose at 20–30% w/w as diluent, croscarmellose sodium at 2–4% w/w as disintegrant, and magnesium stearate at 0.5–1.0% w/w as lubricant in a V-blender operated at 15 rpm for 15–30 minutes; magnesium stearate is added in the final 3–5 minutes to prevent overlubrication and delayed disintegration. Compression on a 16–20 station rotary tablet press at 30–50 rpm turret speed and 15–25 kN compression force produces tablets with hardness 60–90 N as measured per USP <1217>, friability not more than 1.0% per USP <1216>, and thickness 4.5–6.0 mm. Disintegration time in 900 mL water at 37°C ± 2°C must not exceed 15 minutes per USP <701>. Dissolution testing uses USP <711> Apparatus II (paddle method) at 50 rpm in 900 mL degassed water at 37°C, with a typical acceptance criterion of Q = 70% of labelled baicalin content released at 45 minutes under Chinese Veterinary Pharmacopoeia guidance for botanical tablet monographs. Published dissolution data for this specific Shuanghuang Kuxian configuration is limited; method transfer into routine release testing requires validation per USP <1092>. The finished tablet is intended for oral administration to swine, poultry, or companion animals, with the terminal dosage form being a film-coated or sugar-coated tablet of 500–800 mg mass.

What Capsule Fill Weight Variance Arises From Manual Versus Automated Powder Dosing?

In automated production environments, fill weight variance of the spray-dried extract powder depends primarily on the dosing mechanism, a dependency arising from the powder's Carr index of 28–35 and its hygroscopicity profile reaching 8% loss on drying within 4 hours of open-tray exposure at 25°C and 70% relative humidity. On automated dosator-type capsule filling machines — for example, a GKF 700 configured with dosing station 4 — the extract powder conditioned with 0.5–1.5% w/w colloidal silicon dioxide and pre-dried to a loss on drying not more than 5.0% achieves fill weight relative standard deviation not more than 2.0% at a target fill of 300–500 mg in size 0 or size 1 hard gelatin capsules. Manual hand-filling or bench-scale capsule devices under the same conditioning protocol produce relative standard deviation in the range 5–10%, which falls outside the acceptance window of USP <905> uniformity of dosage units for filled capsules at label claims below 250 mg extract per unit.

The capsule route serves two distinct veterinary terminal products: compounded capsules for companion animal dosing at 100–250 mg extract per unit, and bulk-filled capsules for flock-level administration where dosing accuracy at the individual animal level is less critical. Pre-drying before encapsulation is mandatory when ambient RH exceeds 60%, and the dried powder must be filled within 12 hours of tray removal from the dryer or re-conditioned. Disintegration of the filled capsule per USP <701> requires complete shell rupture and content release within 15 minutes in 900 mL water at 37°C ± 2°C. The finished capsule incorporates lactose monohydrate or microcrystalline cellulose as filler to adjust tap density and is packaged in aluminium/polyethylene blister packs with desiccant when intended for humid tropical distribution channels.

Across the three solid dosage routes, water-soluble carrier selection governs the granule and premix manufacturing trajectory because the undiluted extract powder does not disperse uniformly in drinking water at therapeutic dilution. For water-soluble granules, the powder is dry-blended with dextrose monohydrate or lactose monohydrate at a dilution ratio of 1:10 to 1:50 (w/w) in a ribbon blender operated at 25 rpm for 15–20 minutes; blend uniformity acceptance per USP <905> requires an acceptance value not more than 15.0 across 10 sampling units. The finished granule is packaged in foil-lined polyethylene bags at a unit fill of 100–500 g. Reconstitution time in 10 L of municipal water at 25°C with agitation at 200–400 rpm must not exceed 5 minutes; residual insoluble fraction is determined by filtration through a 75 µm stainless steel sieve, with not more than 2% of label mass retained. In hard-water regions, calcium and magnesium ion concentrations above 150 mg/L expressed as CaCO₃ produce visible haze and flocculation within 30 minutes because flavonoid glucuronides interact with divalent cations; incorporation of disodium edetate (EDTA-Na₂) at 0.05–0.1% w/w of the granule mass suppresses this precipitation, but chelator addition must be validated against the actual water source used on the production farm.

For feed premix applications, the powder is diluted to 2–5 kg per metric tonne of complete feed using ground rice hulls or calcium carbonate as carrier in a double-ribbon mixer of 1,000–2,000 L capacity; premix uniformity is tested per the Chinese Veterinary Pharmacopoeia premix monograph with acceptance limits aligned to USP <905>. Pelletised feed processing introduces a thermal conflict: extrusion and pellet conditioning at 90–120°C for 30–60 seconds produces measurable chlorogenic acid degradation to quinoid oxidation products and partial volatilisation of matrine-class alkaloids donated by the Sophora flavescens fraction. Production-scale feed mills therefore apply the premix either by post-pellet liquid spray adsorption onto cooled pellets maintained below 40°C or by low-temperature expander processing at 70–80°C; marker recovery is verified by HPLC analysis after 30 days of ambient warehouse storage. Published data for this specific Shuanghuang Kuxian configuration in pelleted feed is limited; the thermal limits stated here derive from stability data for chlorogenic acid and matrine in analogous botanical feed additives.

When Oral Drinking Water Solutions Require Preservation Beyond 72 Hours

Because reconstituted product in farm dosing tanks remains in ambient contact for more than 72 hours, the preparation of a liquid oral solution or suspension concentrate from the veterinary-grade powder requires preservative efficacy testing before release for field use. The liquid concentrate is prepared at 5–10 mg/mL total extract solids in deionized or distilled water, pH adjusted to 7.0–7.5 with 0.1 mol/L sodium hydroxide under agitation at 200–400 rpm. Preservative selection is limited by the pH window: sodium benzoate at 0.1% w/v or potassium sorbate at 0.15% w/v is incorporated, and antimicrobial effectiveness testing per USP <51> must demonstrate a reduction of not less than 1.0 log10 within 7 days and not less than 3.0 log10 within 14 days for bacterial challenge organisms; yeasts and moulds must remain at or below the initial inoculum count through 28 days. The two preservatives are active only in the undissociated acid form, and formulation above pH 7.5 substantially reduces their efficacy — a processing conflict that imposes the upper pH boundary for the concentrate.

The lower pH boundary is governed by precipitation: baicalin solubility falls below 1 mg/mL at pH 6.5 and the solution develops visible turbidity within 30 minutes under static storage. The resulting processing window of pH 7.0–7.5 is therefore narrower than for the injectable formulation. Light exposure introduces a second degradation vector: chlorogenic acid undergoes photodegradation with formation of brown quinoid polymers; amber polyethylene terephthalate or amber Type III glass containers are specified for the solution concentrate, and bulk dosing tanks on farm should be opaque or shielded. Stability follows the ICH Q1A(R2) protocol: long-term storage at 25°C ± 2°C / 60% RH ± 5% RH, accelerated at 40°C ± 2°C / 75% RH ± 5% RH for 6 months. Operational incompatibilities include acidified drinking water lines operating below pH 5.5 — which precipitate flavonoid glucuronides — and chlorinated water supplies above 4 ppm free chlorine concentration, where hypochlorous acid reacts rapidly with chlorogenic acid and the polyphenol fraction. The terminal finished product is administered at an in-use dilution of 0.1–1.0 g of concentrate per litre of drinking water for poultry and swine, with medicated water consumption monitored to ensure therapeutic dose delivery.

The powder is sifted through a 60-mesh (250 µm) sieve, blended with lactose monohydrate at a 1:5 ratio in a pony mixer for 20 minutes, and packed in double polyethylene bags with silica gel desiccant at a fill weight of 20 kg per bag for distribution to compounding pharmacies; compliance with USP <795> non-sterile compounding and the Chinese Veterinary Pharmacopoeia powder monograph is verified on the compounded finished product.